Medtronic plc·4

Feb 26, 5:48 PM ET

KIIL HARRY SKIP 4

4 · Medtronic plc · Filed Feb 26, 2026

Research Summary

AI-generated summary of this filing

Updated

Medtronic (MDT) EVP Harry Kiil Exercises Options, Sells Shares

What Happened
Harry Kiil, EVP & President, Cardiovascular at Medtronic (MDT), exercised stock options on Feb 19, 2026 to acquire 50,876 shares and completed multiple open-market sales the same day. Exercise entries: 30,568 shares at $93.08 ($2,845,269), 19,923 shares at $87.76 ($1,748,442), and 385 shares at $80.00 ($30,800) — total exercise cost ≈ $4.62M. Open-market sales that day totaled 52,524 shares for proceeds of ≈ $5.13M (weighted average sale price reported; see footnote). The Form 4 shows corresponding derivative disposals at $0, which is consistent with exercising options and immediately selling shares (cashless exercise or simultaneous sale).

Key Details

  • Transaction date: Feb 19, 2026; Form 4 filed Feb 26, 2026 (filed 7 days after transaction; appears later than the usual 2-business-day Form 4 filing requirement).
  • Options exercised (acquisitions): 50,876 shares at strikes of $80.00–$93.08, total exercise cost ≈ $4,624,511.
  • Open-market sales (dispositions): 52,524 shares across multiple trades; total proceeds ≈ $5,132,217. Reported sale prices ranged from $97.60 to $97.775 (weighted-average reported per footnote).
  • Net cash difference (sales minus exercise cost) ≈ $507,706 before taxes/withholdings (simple arithmetic, not a statement of realized gain after tax).
  • Footnotes: F1 — 239 shares acquired via dividend reinvestment since last report. F2 — weighted average sale price reported; individual sale prices ranged $97.60–$97.775; detailed breakdown available on request.
  • Shares owned after the transaction: not specified in the summary data provided in your request; see the full Form 4 for post-transaction holdings.

Context

  • This pattern (exercise of options followed by immediate sale of shares and derivative disposals reported at $0) is typical of a cashless exercise or simultaneous sell-to-cover to pay exercise cost and tax withholding; the filing shows both the option exercise (M code) and open-market sales (S code).
  • Sales do not necessarily indicate negative views by the insider; when paired with immediate option exercises they frequently reflect routine compensation/vesting and tax-management activity rather than a directional bet.
  • If you want the full breakdown of holdings after the transactions or the precise per-trade sale prices, the Form 4 filing (accession 0001708062-26-000002) provides the detailed tables and can be requested from the SEC or issuer.

Insider Transaction Report

Form 4
Period: 2026-02-19
KIIL HARRY SKIP
EVP & President Cardiovascular
Transactions
  • Exercise/Conversion

    Ordinary Shares

    [F1]
    2026-02-19$93.08/sh+30,568$2,845,26964,984 total
  • Exercise/Conversion

    Ordinary Shares

    2026-02-19$87.76/sh+19,923$1,748,44284,907 total
  • Exercise/Conversion

    Ordinary Shares

    2026-02-19$80.00/sh+385$30,80085,292 total
  • Sale

    Ordinary Shares

    2026-02-19$97.86/sh1,648$161,27383,644 total
  • Sale

    Ordinary Shares

    [F2]
    2026-02-19$97.66/sh30,568$2,985,37553,076 total
  • Sale

    Ordinary Shares

    2026-02-19$97.77/sh19,255$1,882,56133,821 total
  • Sale

    Ordinary Shares

    2026-02-19$97.83/sh668$65,34733,153 total
  • Sale

    Ordinary Shares

    2026-02-19$97.82/sh385$37,66132,768 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2026-02-1930,56811,606 total
    Exercise: $93.08From: 2023-08-01Exp: 2032-08-01Ordinary Shares (30,568 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2026-02-1919,92318,926 total
    Exercise: $87.76From: 2024-07-31Exp: 2033-07-31Ordinary Shares (19,923 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2026-02-193851,155 total
    Exercise: $80.00From: 2025-07-29Exp: 2034-07-29Ordinary Shares (385 underlying)
Footnotes (2)
  • [F1]Includes 239 shares acquired through dividend reinvestment since the last report filed by the reporting person.
  • [F2]The price reported is a weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $97.60 to $97.775. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder upon request.
Signature
/s/ Patricia Walesiewicz, attorney-in-fact|2026-02-26

Documents

1 file
  • 4
    wk-form4_1772146125.xmlPrimary

    FORM 4